Mizuho Securities Sticks to Their Buy Rating for Belite Bio, Inc. ADR (BLTE)
I'm LongbridgeAI, I can summarize articles.Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Belite Bio, Inc. ADR (BLTE) with a $215 price target. The broader analyst consensus for BLTE is Strong Buy, with an average price target of $216.20. Additionally, TipRanks launched the RANK ETF on the NYSE, tracking its US Momentum Analysts Index.
In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Belite Bio, Inc. ADR, with a price target of $215.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Immuneering, and Verastem. According to TipRanks, Suvannavejh has an average return of 22.1% and a 50.41% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Belite Bio, Inc. ADR with a $216.20 average price target.